BRIEF-Erasca Initiates Seacraft-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib In Patients With Nras-Mutant Melanoma

Reuters06-18

June 18 (Reuters) - Erasca Inc :

* ERASCA INITIATES SEACRAFT-2 PIVOTAL PHASE 3 TRIAL EVALUATING NAPORAFENIB PLUS TRAMETINIB IN PATIENTS WITH NRAS-MUTANT MELANOMA

* ERASCA INC - RANDOMIZED STAGE 1 READOUT FOR NAPORAFENIB PLUS TRAMETINIB VERSUS. TRAMETINIB MONOTHERAPY EXPECTED IN 2025

* ERASCA INC - FAVORABLE MOS AND MPFS DEMONSTRATED IN POOLED ANALYSIS OF PHASE 1B AND PHASE 2 TRIALS IN NRASM MELANOMA

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2444481750?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-06-18 20:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2444481750","market":"us","top_or_hot":-1,"title":"BRIEF-Erasca Initiates Seacraft-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib In Patients With Nras-Mutant Melanoma","media":"Reuters","content":"<html><body><p>June 18 (Reuters) - Erasca Inc   :</p><p>   * ERASCA INITIATES SEACRAFT-2 PIVOTAL PHASE 3 TRIAL EVALUATING NAPORAFENIB PLUS TRAMETINIB IN PATIENTS WITH NRAS-MUTANT MELANOMA</p><p>   * ERASCA INC - RANDOMIZED STAGE 1 READOUT FOR NAPORAFENIB PLUS TRAMETINIB VERSUS. TRAMETINIB MONOTHERAPY EXPECTED IN 2025</p><p>   * ERASCA INC - FAVORABLE MOS AND MPFS DEMONSTRATED IN POOLED ANALYSIS OF PHASE 1B AND PHASE 2 TRIALS IN NRASM MELANOMA</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Erasca Initiates Seacraft-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib In Patients With Nras-Mutant Melanoma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Erasca Initiates Seacraft-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib In Patients With Nras-Mutant Melanoma\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-18 20:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>June 18 (Reuters) - Erasca Inc   :   * ERASCA INITIATES SEACRAFT-2 PIVOTAL PHASE 3 TRIAL EVALUATING NAPORAFENIB PLUS TRAMETINIB IN PATIENTS WITH NRAS-MUTANT MELANOMA   * ERASCA INC - RANDOMIZED STAGE ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2444481750","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2444481750","pubTimestamp":1718712776,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"June 18  - Erasca Inc   :   * ERASCA INITIATES SEACRAFT-2 PIVOTAL PHASE 3 TRIAL EVALUATING NAPORAFENIB PLUS TRAMETINIB IN PATIENTS WITH NRAS-MUTANT MELANOMA   * ERASCA INC - RANDOMIZED STAGE 1 READOUT FOR NAPORAFENIB PLUS TRAMETINIB VERSUS. TRAMETINIB MONOTHERAPY EXPECTED IN 2025   * ERASCA INC - FAVORABLE MOS AND MPFS DEMONSTRATED IN POOLED ANALYSIS OF PHASE 1B AND PHASE 2 TRIALS IN NRASM MELANOMASource text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4539":"次新股","ERAS":"Erasca, INC."},"translate_title":"简介-Erasca启动Seacraft-2关键3期试验，评估Naporafenib联合曲美替尼治疗Nras突变型黑色素瘤患者的疗效","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ERAS":1},"content_text":"June 18 (Reuters) - Erasca Inc   :   * ERASCA INITIATES SEACRAFT-2 PIVOTAL PHASE 3 TRIAL EVALUATING NAPORAFENIB PLUS TRAMETINIB IN PATIENTS WITH NRAS-MUTANT MELANOMA   * ERASCA INC - RANDOMIZED STAGE 1 READOUT FOR NAPORAFENIB PLUS TRAMETINIB VERSUS. TRAMETINIB MONOTHERAPY EXPECTED IN 2025   * ERASCA INC - FAVORABLE MOS AND MPFS DEMONSTRATED IN POOLED ANALYSIS OF PHASE 1B AND PHASE 2 TRIALS IN NRASM MELANOMASource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2444481750"}